VRCA Valuation

Verrica Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

6.200

-0.8(-11.429%)1D

Overview
Forecast
Valuation
Earnings

VRCA Relative Valuation

VRCA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRCA is overvalued; if below, it's undervalued.

Historical Valuation

Verrica Pharmaceuticals Inc (VRCA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.01 is considered Undervalued compared with the five-year average of -4.39. The fair price of Verrica Pharmaceuticals Inc (VRCA) is between 26.75 to 27.36 according to relative valuation methord. Compared to the current price of 0.71 USD , Verrica Pharmaceuticals Inc is Undervalued By 97.33%.

Relative Value

Fair Zone

26.75-27.36

Current Price：0.71

97.33%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-3.48

P/B

Median3y

19.42

Median5y

14.24

-80.39

FCF Yield

Median3y

-40.93

Median5y

-29.86

Competitors Valuation Multiple

The average P/S ratio for VRCA's competitors is 494.32, providing a benchmark for relative valuation. Verrica Pharmaceuticals Inc Corp (VRCA) exhibits a P/S ratio of 2.83, which is -99.43% above the industry average. Given its robust revenue growth of -10.12%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VRCA.O

Verrica Pharmaceuticals Inc

2.83

Average P/S: 494.32

-10.12%